Project Grant R41CA298584
Award Date
8/1/25
Completion Date
7/31/26
Dollars Obligated
$396K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
South Carolina, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Cold Spring Harbor Laboratory provides $640,583 to enhance the efficacy of immunotherapy against metastatic colorectal cancer. The primary goal is to activate the PPARD-CPT1A axis in CD8+ T cells to boost their metabolic fitness and anti-tumor activity within the tumor microenvironment. The research aims to delineate the mechanisms by which PPARD activation improves CD8+ T cell...
The National Cancer Institute (NCI) awarded a $154,642 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research. The grant, titled "Targeting the Evolving Immunopeptidome of Metastatic Colorectal Cancer," aims to systematically elucidate the evolving immunopeptidome from normal colon, primary tumor, and metastatic lesion patient-derived organoids (PDOs) through mass spectrometry. This will identify conserved...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $546,625.00 to the University of Pittsburgh to develop a novel nanocarrier-based immunochemotherapy for the treatment of metastatic colorectal cancer (mCRC). The key products and services to be delivered include: Developing and characterizing a nanoparticle carrier capable of co-delivering small interfering RNA targeting the IRHOM1 protein and a prodrug conjugate of...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $205,700.00 to the Sloan-Kettering Institute for Cancer Research to conduct research aimed at overcoming rapid resistance to targeted therapies in colorectal cancer. The key products and services to be delivered under this 2-year award include: Evaluating how intrinsic tumor features modulate the development of resistance to targeted therapies in colorectal cancer through analysis of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $406,611.00 to the University of Texas Health Science Center at Houston to investigate the role and therapeutic targeting of the GPR56 protein in colorectal cancer. The key objectives are to: Characterize the role and signaling mechanisms of GPR56 in colorectal cancer stem cells and metastasis using patient-derived organoids. Develop and evaluate highly potent GPR56-targeted...
The National Cancer Institute (NCI) awarded a $151,000 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to The Medical University of South Carolina (MUSC) to investigate the role of polyploid cancer cells in high-grade serous ovarian carcinoma (HGSOC). The project aims to: 1) Define essential genes for the polyploid cancer cell lifecycle and its critical transition stages using CRISPR-Cas9 screening, and 2) Determine the expression of putative polyploid cancer...
The National Cancer Institute (NCI) awarded a $406,258 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Georgia State University Research Foundation Inc. on July 15, 2025. The grant supports research to develop novel covalent anti-cancer drugs using phosphorus fluoride exchange (PFEX) click chemistry. The key objectives are to: 1) synthesize PFEX warheads with different substituents to optimize stability and reactivity, 2) compare PFEX warheads to α,β-unsaturated carbonyl warheads,...
This National Cancer Institute (CFDA 93.396 Cancer Biology Research) Project Grant award of $560,297 to the Icahn School of Medicine at Mount Sinai supports research to functionally characterize oncofetal stem cells (ONFSCs) in colorectal cancer (CRC). The key objectives are to: Generate phenotypic transcriptional reporters to track the dynamics of LGR5+ cancer stem cells (CSCs) and ONFSCs, and use these to dissect the functional interplay between these stem cell populations. Employ a multi-omic...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $338,828 to Bioplatinum Technologies LLC to study the effects of new platinum anticancer drugs in pancreatic cancer. The project aims to exploit the high levels of chondroitin-4-sulfate (C4S) glycosaminoglycans in pancreatic tumors to enhance the delivery and efficacy of the polynuclear platinum complex (PPC) drug triplatin. The research will evaluate triplatin as a potential...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Treatment Research Grant Program (CFDA 93.395), is providing $572,254 over a 3-year period starting February 1, 2025 to identify the first selective inhibitors of PLC𝜸1 and PLC𝜸2. The research aims to screen 200,000 compounds to discover small molecule inhibitors of these two phospholipase C gamma enzymes, which have been implicated in driving oncogenesis. The project will employ high-throughput screening...